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Using archived tumours, those from 1984–1986 and 1996–1997 underwent immunohistochemistry for hormone receptors and
grade analysis. A significant shift towards more ER-positive and low-grade disease was found; this appears to reflect screening
practices, but could still influence survival.
British Journal of Cancer (2009) 100, 807–810. doi:10.1038/sj.bjc.6604934 www.bjcancer.com
Published online 17 February 2009
& 2009 Cancer Research UK
Keywords: breast; epidemiology; hormone receptor status; survival
                            
Breast cancer is the commonest cancer in women in the United
Kingdom, with over 40000 cases diagnosed annually, and the
incidence is increasing. Survival rates are also increasing partly
due to advancements in hormonal and chemotherapeutic manage-
ment, in addition to a trend towards multidisciplinary manage-
ment and specialist surgeons. The UK nationwide mammographic
screening programme was also designed to reduce mortality. It has
been suggested that the epidemiology of breast cancer may have
changed over time, with more oestrogen receptor (ER)-positive
tumour than in the past (Pujol et al, 1994; Bradburn et al, 1998; Li
et al, 2003; Glass et al, 2007). However, studying retrospective data
on ER status has the disadvantage that the assays used to establish
ER status, and hence their sensitivity and specificity have changed
over time. We, therefore, examined trends in the molecular biology
of breast cancers in patients from two large centres in Glasgow by
performing immunohistochemistry on archived tumour samples,
thereby avoiding artefactual changes in receptor status over time.
We also examined the survival of study patients.
MATERIALS AND METHODS
Patient selection
This study aimed to compare the molecular phenotype of stored
tissue samples from two separate cohorts of patients, defined by
the period in which they had their surgery. All female patients who
had surgery for operable breast cancer at two teaching units in
Glasgow during 1984–1986 and 1996–1997 were identified. The
study had the approval from local ethics committee. Full
pathological, demographic, screening and 5-year survival data
were either available from the Scottish Cancer Registry or obtained
from the patient’s case record or pathology records. Deprivation
status was ascertained using established postcode Carstairs
deprivation categories (1–7) derived from 1981 or 1991 census
data. For each patient, an archived paraffin-embedded tumour
block was searched for within the relevant pathology department.
Following sample size determination, there were originally 1076
patients (423 in 1984–1986 (cohort 1) and 653 in 1996–1997
(cohort 2)) from which 900 tumour blocks were available for
analysis (323 and 577 in cohorts 1 and 2, respectively).
Tumour sections were prepared according to routine patho-
logical techniques, and then sent to a pathologist for determination
of tumour grade using the modified Scarff–Bloom–Richardson
scale and marking of suitable tumour areas. Three 0.6-mm circular
cores were then taken from the marked areas in each tumour block
and placed into paraffin blocks in tissue microarray format.
Sections from each block were taken for ER immunohisto-
chemistry, Her-2 receptor and progesterone receptor (PR) to be
performed; each full set of sections underwent ER, PR or HER-2
immunohistochemistry at the same time. In all, 862 of the 900
samples (95%) underwent grade analysis, and 20% of the tumours
in cohort 1 and 19% of tumours in cohort 2 did not undergo ER
immunohistochemistry due to fragmented cores or absence of
tumour in the core. For the same reasons, 14% of tumours in
cohort 1 and 10% in cohort 2 did not undergo PR immuno-
histochemistry, and 15% of tumours in cohort 1 and 18% of
tumours in cohort 2 did not undergo Her-2 staining.
Oestrogen receptor immunohistochemistry was carried out
using Novocastra 6F11 mouse antihuman ER (Novocastra,
Newcastle-Upon-Tyne, UK) with a manual protocol at a dilution
of 1:50, with epitope retrieval carried out using EDTA at pH 8.0
with a microwave pressure cooker technique for 5min. After the
primary antibody step, slides were refrigerated overnight, with the
rest of the steps carried out at room temperature. Progesterone
receptor immunohistochemistry was carried out using Dako 636
mouse antihuman PR (Dako, Ely, UK), using a dilution of 1:50
and epitope retrieval using citrate pH 6.0 and a microwave
pressure cooker technique for 5min, with the final protocol being
carried out at room temperature using a Dako Autostainer. Her-2
immunohistochemistry was carried out in a Dako Autostainer at
room temperature using the standard Dako Herceptest protocol.
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Once immunohistochemistry had been carried out, each core was
assessed by light microscopy and scored by an experienced scorer
using a weighted histoscore ((% tumour cells scoring at intensity 1)
þ(2 % scoring at intensity 2)þ(3 % scoring at intensity 3)). As
each tumour had been cored in triplicate, a mean histoscore for each
core was calculated. For ER and PR, ‘positive’ was taken as a
histoscore of 10 or over, and for Her-2, positivity was taken as a
histoscore of 90 or over. A second experienced scorer examined
10% of the cores (Kirkegaard et al, 2006). Statistical analysis was
performed using SPSS statistics software (SPSS, Chicago, IL, USA),
version 14.0. Comparison of the demographics of the two groups was
carried out using w
2-analysis (Fisher’s exact test in one case where
numbers were small). Comparison of the molecular profiles in the
groups was carried out using w
2-analysis for hormone receptor
or grade status, t-test to compare mean receptor levels and
Mann–Whitney test to compare median receptor levels. A multi-
variate analysis was performed using binary logistic regression to
assess whether age, screening and deprivation affected the percen-
tage of ER-positive tumours in the groups. Initial tests suggested that
there was not a direct linear relationship between ER and age, but
ER-positivity rates increased from 60 years of age, and hence ‘age
over or under 60’ as a categorical variable was included in the
regression. Kaplan–Meier survival analysis (censored to 5 years) was
carried out, using the log-rank test to test for difference between the
groups. Stepwise Cox’s proportional hazard regression was carried
out to compare factors influencing survival.
RESULTS
The demographics of the patients whose tumour blocks were
available are seen in Table 1. All tumours in cohort 1 had been
detected symptomatically rather than by screening, the screening
programme having yet to be introduced in Scotland.
A comparison of the results of immunohistochemistry based on
cohort (and screening status within the 1996–1997 cohort) is
presented in Table 2. In a multivariate analysis, the significance of
the impact of cohort period (1984–1986 or 1996–1997) on ER
status did not persist after correction for percentage of patients
aged over 60 and screening status, in combination with other
factors or on their own. Oestrogen receptor positivity within each
10-year-age range increased from 1984–1986 to 1996–1997
(except in those under 30 years), although the numbers involved
meant that this did not approach statistical significance. Table 3
shows Cox’s proportional hazard regression analysis of survival;
Table 1 Patient demographics
1984–1986 1996–1997
P for
difference
Mean age at diagnosis 56.9 58.4 0.049
Median age at diagnosis 59 58 0.179
Percentage detected at screening 0 29 o0.001
Percentage of patients in each deprivation category
Affluent 12 17
Intermediate 41 47 0.05
Deprived 47 36
Node positive 59.3 42.4 0.001
Table 2 Results
Cohort 1 1984–1986 Cohort 2 1996–1997 Cohort 2 Symptomatic Cohort 2 Screened
Grade distribution:
percentage grades 1, 2 and 3
8, 49.2 and 42.9 14.9, 48.3 and 36.8 12.2, 46.8 and 41 22.3, 53 and 24.7
P¼0.009 for vs cohort 1 P¼0.2 for vs cohort 1 Po0.001
for vs cohort 2 symptomatic
ER-positive tumours 64.2% 71.5% 68.8% 78.4%
(P¼0.042) P¼0.325 for vs cohort 1 P¼0.024
for vs cohort 2 symptomatic
Mean ER score 97.1 102
(P¼0.454)
Median ER score 104.2 120
(IQR 0–190) (IQR 0–180)
(P¼0.774)
PR-positive percentage 44.9 49.9
(P¼0.181)
Mean PR score 41.2 37.9
(P¼0.418)
Median PR score 0 8.3
(IQR 0–80) (IQR 0–61)
(P¼0.181)
Her-2-positive percentage 21.5% 20.6%
(P¼0.170)
Mean Her-2 score 52.2 43.1
(P¼0.772)
Median Her-2 score 0 0
(IQR 0–50) (IQR 0–67)
(P¼0.773)
ER+/PR+ percentage 42.4 46.7
ER+/PR  percentage 21.8 24.8
ER /PR  percentage 33.3 23.5
ER /PR+ percentage 2.5 5
(P¼0.023)
0.620 0.887 0.874 0.976
5-year breast cancer
cumulative survival
(Po0.001) Po0.001
for vs cohort 1
P¼0.148
for vs cohort 2 symptomatic
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for differences in ER status of the patients alone, the period of
diagnosis (i.e., 1984–1986 or 1996–1997) remained as a significant
independent factor in survival. After correcting, for all the factors
in the model, the effect of the period of diagnosis on survival
persisted, with survival being higher in 1996–1997.
DISCUSSION
A significant change in grade distribution over time was seen in
this study, particularly a reduction in the frequency of grade 3 and
an increase in the frequency of grade 1 tumours, a change that
appeared to be due to screen-detected tumours in cohort 2. The
pathological grade of screen-detected tumours has received much
attention in the literature, these being of lower grade than
symptomatically detected tumours; it is uncertain, however,
whether this represents an interruption of ‘phenotypic drift’ or
simply a longer asymptomatic preclinical phase (Tabar et al, 1999).
This study also showed an increase over time in the percentage of
breast cancers that were ER positive. The increase from 64.2 to 71.5%
was significant on w
2-analysis. The increase did not persist on logistic
regression after adjusting for the prevalence of patients over 60 in the
groups. However, an increase in the percentage of ER positivity
within each 10-year-age group (except those under 30 years) in the
study period, although not reaching statistical significance because of
the numbers in each subgroup, suggests a trend towards the overall
more ER-positive disease in cohort 2. The ER-positive rise also did
not persist after adjustment for the screening status of the patients in
the groups. This almost certainly reflects the fact that screen-detected
tumours are slower growing, and hence more likely to be ER positive
than negative. As there is unlikely to be any phenotypic drift from
ER-positive to ER-negative status within breast cancers, it is possible
that the screening programme has merely detected an excess of
ER-positive breast cancers, which have developed as a result of a
true change in biology.
There was a significant change in combined ER/PR receptor
status over time, most notably a marked decrease in the percentage
of tumours that had the poor prognostic ER-negative/PR-negative
status. The percentage of tumours that were PR positive and Her-2
positive did not change over time; notably, there was no change in
mean score over time for any of the three receptors.
A study of incidence rates of ER-negative and ER-positive breast
cancers in a US health plan found that the incidence rate for
ER-negative disease had remained relatively constant with a
decline from 1999 onwards, whereas for ER-positive disease,
there was a significant increase in incidence throughout the study
period (Glass et al, 2007). Other studies have also suggested
an increase in percentage of ER positivity over time (Pujol et al,
1994; Bradburn et al, 1998; Li et al, 2003). In most of the studies
of trends in ER status over time, the assays and criteria used
to determine ER positivity changed several times during the
study periods. Critically, in this study, we used immuno-
histochemistry on all samples, thereby ruling out an artefactual
increase. Furthermore, all samples underwent immunohisto-
chemistry together to eliminate the potential effect of changing
laboratory conditions on staining. The study was powered to
detect a 10% difference in ER-positive prevalence, and is hence
slightly underpowered to detect the observed 7% difference. The
inability to retrieve tumour block for all patients and fragmented
samples (factors common to studies involving tissue microarrays)
reduced the number of samples in each cohort that were analysed,
but the tumours that underwent analysis should be representative
of the whole cohort.
One explanation for a preferential increase in ER-positive
tumours could be a population-wide change in the prevalence of
factors that increase the frequency of these tumours, such as late
age at first pregnancy, postmenopausal obesity (Potter et al, 1995;
Colditz et al, 2004) and use of hormone replacement therapy
(HRT) (Potter et al, 1995). There is evidence that the percentage of
all children being born to mothers aged 35 years and over is
increasing in Scotland, and that mean BMI and prevalence of
obesity are increasing (Brown et al, 2007). Data on HRT use by the
patients in this study were not available.
A change in ER positivity could influence the survival. In this
study, breast cancer-specific survival in the 1984–1986 cohort was
significantly lower than in 1996–1997. When the effect of period of
diagnosis (i.e., 1984–1986 or 1996–1997) on survival was adjusted
for the ER status of the patients alone, the period of diagnosis
remained a significant independent factor in survival (with
survival being higher in 1996–1997). As expected, the difference
in survival between cohorts is not fully explained by differences in
ER status; treatment and global management changes have
undoubtedly contributed to changes in survival over time
(Bradburn et al, 1998; Thomson et al, 2004). However, a true
change in ER status could also have implications for the
application of data from clinical trials carried out in previous
decades to the women of today, as a change in the prevalence of
ER-positive disease could alter the overall survival benefit seen
from chemotherapy and different hormonal therapies.
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